GC 1109

Drug Profile

GC 1109

Alternative Names: GC-1109

Latest Information Update: 07 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anthrax

Most Recent Events

  • 24 Feb 2016 Green Cross Corporation suspends patient recruitment in a phase II trial for Anthrax (Prevention) in South Korea (NCT01624532)
  • 12 Sep 2015 Phase II development is ongoing in South Korea
  • 01 Nov 2011 Phase-II clinical trials in Anthrax (prevention) in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top